English | Español

Community
+ Community
Kacie Whaley | Oct 6, 2017

Med student with spinal cord injury refuses to give up
+ Regulatory
Kacie Whaley | Oct 6, 2017

AbbVie settles intellectual property dispute with Amgen over Humira
+ Regulatory
Kacie Whaley | Oct 6, 2017

Maviret gets OK as hepatitis C treatment in Japan
+ Community
Kacie Whaley | Oct 6, 2017

Mayo Clinic professor discovers new ALS genes, disease pathways
+ Community
Kacie Whaley | Oct 6, 2017

Uterine microbiome in women may have connection to endometrial cancer, Mayo Clinic says
+ Community
Kathy Adams | Oct 6, 2017

Abbott completes acquisition of Alere
+ Community
Kacie Whaley | Oct 5, 2017

Nurse learned from her heart attack to take signs of illness seriously
+ Community
John Breslin | Oct 5, 2017

Mental health patients face few choices on narrow networks in health care marketplace

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'